title: [A decade of biologics in dermatology].
abstract: Basic research on psoriasis has identified a number of molecular targets which can be of therapeutic interest. While the first two biologics--alefacept and efalizumab--were developed primarily for dermatologists, other agents like cytokine antagonists (TNFα antagonists) were introduced primarily by other medical fields. Knowledge has provided new impulses for research, so that today many therapeutic strategies are being developed, not exclusively limited to biologics. Others branches of dermatology also have benefitted greatly from biologics like ipilimumab or omalizumab.
authors.affiliation: Klinik und Poliklinik für Dermatologie, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland. Gottfried.Wozel@uniklinikum-dresden.de
authors.forename: G
authors.initials: G
authors.lastname: Wozel
authors.forename: M
authors.initials: M
authors.lastname: Meurer
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D012871:Skin Diseases / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D001688:Biological Products; D003879:Dermatologic Agents